TY  - JOUR
AU  - Galldiks, Norbert
AU  - Kocher, Martin
AU  - Langen, Karl-Josef
TI  - Pseudoprogression after glioma therapy: an update
JO  - Expert review of neurotherapeutics
VL  - 17
IS  - 11
SN  - 1744-8360
CY  - Abingdon
PB  - Taylor & Francis Group
M1  - FZJ-2017-06349
SP  - 1109-1115
PY  - 2017
AB  - Introduction: Initial diagnostics and follow-up of gliomas is usually based on contrast-enhanced MRI. However, the capacity of standard MRI to differentiate neoplastic tissue from posttherapeutic effects such as pseudoprogression is limited. Advanced neuroimaging methods may provide relevant additional information, which allow for a more accurate diagnosis especially in clinically equivocal situations. This review article focuses predominantly on PET using radiolabeled amino acids and advanced MRI techniques such as perfusion-weighted imaging (PWI) and summarizes the efforts of these methods regarding the identification of pseudoprogression after glioma therapy.Areas covered: The current literature on pseudoprogression in the field of brain tumors, with a focus on gliomas is summarized. A literature search was performed using the terms ‘pseudoprogression’, ‘temozolomide’, ‘glioblastoma’, ‘PET’, ‘PWI’, ‘radiochemotherapy’, and derivations thereof.Expert commentary: The present literature provides strong evidence that PWI MRI and amino acid PET can be of great value by providing valuable additional diagnostic information in order to overcome the diagnostic challenge of pseudoprogression. Despite various obstacles such as the still limited availability of amino acid PET and the lack of standardization of PWI, the diagnostic improvement probably results in relevant benefits for brain tumor patients and justifies a more widespread use of these diagnostic tools.
LB  - PUB:(DE-HGF)16
C6  - pmid:28862482
UR  - <Go to ISI:>//WOS:000414154300006
DO  - DOI:10.1080/14737175.2017.1375405
UR  - https://juser.fz-juelich.de/record/837424
ER  -